Editorial

US FDA approved a fixed-dose combination tablet containing Sofosbuvir 400mg and Velpatasvir 100 mg and is the first to treat all six major forms of HCV on June 28, 2016. The first brand was approved is “Epclusa” of Gelead Sciences to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease), for patients with moderate to severe cirrhosis (decompensated cirrhosis). Epclusa is approved for use in combination with the drug ribavirin.

The first generic version of this product developed by Beacon Pharma of Bangladesh named Sofosvel is already on the market.

Sofosbuvir 400 mg + Velpatasvir 100 mg Tablet & Bulk have been approved by CDSCO for the treatment of adult patients with -chronic Hepatitis C virus, Genotype 1,2,3,4,5 or 6 infection.-Without cirrhosis or with compensated cirrhosis-Without decompensated with chronic for use in combination with Ribavirin on 04.05.2017. The first generic version of Epclusa was developed and launched in the market by Natco Pharma in the month of May 2017.

Normal dosage regimen of this drug is 12 weeks and the cost of innovator brand Epclusa is $74760 (RS. 4788378) whereas the cost of generic version developed by Natco Pharma (Velpanat) is Rs. 55500. The price of generic version is about 1 percent of the innovator brand. Apart from Natco Pharma 10 more Indian companies have got licence from Gelad Sciences for manufacturing the same drug. Hope price of this drug will be cheaper in future improving access to this drug.
Pharmacovigilance Division, Indian Pharmacopoeia Commission, MOH is now recognized as one of the six WHO Collaborating Centres round the globe

Drug Safety Alerts by PvPI during June 2017
Health care professionals, Patients/Consumers has been advised to closely monitor the possibility of the below mentioned adverse events associated with the use of the mentioned drugs. If such events are encountered they are requested to report to the NCC-PvPI either by filling of Suspected Adverse Drug
The preliminary analysis of ADRs from the PvPI database reveals that the following drugs are associated with the risks as given below.

<table>
<thead>
<tr>
<th>Sl. No</th>
<th>Suspected Drugs</th>
<th>Indication</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Paracetamol</td>
<td>Mild to moderate pain including dysmenorrhoeal pain, headache; pain relief in osteoarthritis and soft tissue lesions; pyrexia including postimmunisation pyrexia; acute migraine attack</td>
<td>Baboon Syndrome</td>
</tr>
<tr>
<td>2.</td>
<td>Lamivudine</td>
<td>HIV infection in combination with at least two other antiretroviral drugs</td>
<td>Hearing Loss</td>
</tr>
<tr>
<td>3.</td>
<td>Mebeverine</td>
<td>For Irritable Bowel Syndrome (IBS)</td>
<td>Retrosternal Pain</td>
</tr>
</tbody>
</table>

**India grants Pfizer patent for blockbuster brand Prevenar 13**  
India has granted US drug giant Pfizer a patent for its blockbuster Prevenar 13, a vaccine that helps prevent cases of pneumonia, one of the leading causes of deaths of children under five years of age. The approval comes more than a decade after the company applied for the patent in the country. Global medical humanitarian organisation Médecins Sans Frontières (MSF) said it is a “major setback” to hopes for an affordable vaccine and is likely to legally challenge the patent approval. Prevenar 13 helps prevent pneumococcal pneumonia and infections caused by 13 strains of streptococcus pneumonia bacteria, according to Pfizer.

This vaccine and GlaxoSmithKline's Synflorix are the only two pneumococcal conjugate vaccines (PCV) available in the country. In the private market, Prevenar 13 is priced at Rs 3,800 per dose, and Synflorix at Rs 1,800 per dose, industry insiders said. Three doses are required for each child, they said.


**FDA panel to review pediatric cough medicine with opioids**  
The FDA's Pediatric Advisory Committee will evaluate the use of cough medications with opioids such as codeine and hydrocodone in children, including benefit-risk considerations and current treatment procedures, on Sept. 11 after an FDA meeting in which the American Academy of Pediatrics and other health care organizations opposed opioid use for pediatric cough treatment. "All of this work is essential to reducing preventable harm from opioid-containing medications and keeping children safe," said FDA Commissioner Scott Gottlieb.


**Johnson & Johnson and CSIR-IMTECH collaborate on tuberculosis treatment R&D**  
Johnson & Johnson and India's Institute of Microbial Technology, part of the Council of Scientific and Industrial Research, will collaborate on the research and development of new drug compounds for tuberculosis. The partnership will take advantage of J&J’s research capabilities and CSIR-IMTECH's microbial technology competence.


**Study examines potential use of gold nanoparticles in cancer treatment**  
A UK animal study published in the journal Angewandte Chemie found that gold particles catalyzed a directed chemical reaction in zebrafish brains, in addition to activating lung cancer drugs in a petri dish, suggesting that the approach could be used to release drugs inside tumors. "We hope that a similar device in humans could one day be planted by surgeons to activate chemotherapy directly in tumors and reduce harmful effects in healthy organs," said author Asier Unciti-Broceta.

NPPA threatens legal action against 40 hospitals for not displaying knee implant prices

National drug pricing regulator NPPA has said 40 hospitals, including Medanta Medcity and Apollo Spectra in the national capital, will face action for not displaying prices of knee implants on their websites.

The National Pharmaceutical Pricing Authority (NPPA) on its Twitter handle released a list naming 40 hospitals across the country that will face action.

"40 hospitals not displaying knee implant prices on their websites to face action", the regulator said in a tweet.

NPPA, however, did not elaborate on the action it has envisaged.

Hospitals that have been named in the list include Rockland Hospital (Delhi), Moolchand Medcity (Delhi), Apex Multi Speciality Hospital (Varanasi & Mumbai), Vijaya Hospitals (Chennai) and Sahara Hospital (Lucknow).

Besides some hospitals located in cities like Noida, Patna, Bhopal, Ahmedabad and Kanpur have also been named in the list.

The authority in a memorandum on August 18 had asked all manufacturers /importers and marketers and hospitals to comply with the notified ceiling price of orthopaedic knee implant system.

The government on August 16 fixed a price range for knee implants from ₹ 54,000 to ₹ 1.14 lakh, nearly 70 per cent lower than their earlier cost.

"After cardiac stents, we have now decided to bring all kinds of knee implants under price control. In our country 1.5 to 2 crore people suffer from knee problems, who need health assistance," Chemicals and Fertilisers Minister Ananth Kumar had said in a news briefing.

The minister had also warned of stringent action against hospitals, importers, retailers if they charged in excess of the MRP saying that the government would recover excess profit from such knee implants with 18 per cent interest and may also cancel licences of hospitals.

The government had in February slashed the maximum price of life-saving heart stents implants by up to 85 per Earlier, the average maximum retail price (MRP) for BMS was ₹ 45,000 and for DES, it was ₹ 1.21 lakh. cent by capping them at ₹ 7,260 for bare metal ones and ₹ 29,600 for drug eluting variety.

Ref. ET Health

Forthcoming Events:

9th Indian Pharmaceutical Association (IPA) Students Congress
September 2nd – 3rd, 2017
Venue: Vikash Institute of Pharmaceutical Sciences
Rajmundri, Andhra Pradesh
For Details:
http://www.ipapharma.org/events/IPASF%2020B

Pharmacists Day 2017 celebration
Indian Pharmaceutical Association, Bengal Branch
Date: 25th September 2017
Theme:"From research to health care: Your pharmacist is at your service”

Congratulations !!!

Prof. B.Suresh, Past President, IPA has been conferred Fellowship of Commonwealth Pharmacists Association (CPA) for his significant contribution in uplifting the standards of pharmacy profession during the 13th Biennial CPA conference held during 28-30th July, 2017 at Sydney, Australia

DISCLAIMER:
The Newsletter intends to provide updated and reliable information on medicines and other related issues in an attempt to equip healthcare professionals to take informed decision in recommending medicines to the patients. However, they are encouraged to validate the contents. None of the people associated with the publication of the Newsletter nor the organization shall be responsible for any liability for any damage incurred as a result of use of contents of this publication. The brand names of medicines, if mentioned, are for illustration only and the Newsletter